long intergenic non-protein coding RNA 1050Genealiases: []
Q-omics provides the consensus-scored LINC01050 profile across patient tissues and cancer cell-line models. LINC01050 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01050 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, LINC01050 RNA expression shows 16,051 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where LINC01050 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01050 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01050 survival associations across molecular data types. LINC01050 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01050 RNA expression–survival associations across cancer types. High LINC01050 expression shows unfavorable associations in UVM, KIRC, THYM, ACC, LUAD and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01050 RNA expression.
This table summarizes LINC01050 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01050. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01050 shows higher tumor expression in HNSC, COAD, BLCA, LUSC, STAD and BRCA. The HNSC box plot shows higher LINC01050 RNA expression in tumor versus normal tissue (log2 FC = +0.489, t-test p < 0.001).
This table shows molecular features associated with LINC01050 in patient tissues and cancer cell lines. In patient samples, LINC01050 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
